Pfizer drops plan for twice-daily obesity pill due to side effects
By Hannah Kuchler & Donato Paolo Mancini
Why Pfizer's stumble in the obesity market is a boon for Eli Lilly
By Kevin Stankiewicz
Pfizer drops twice-daily version of obesity pill over side effects
By Michael Erman & Manas Mishra
Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects
By Annika Kim Constantino
Pfizer's twice-daily weight loss pill joins a long list of obesity drug flops
By Annika Kim Constantino